Le Lézard
Classified in: Health
Subjects: PER, CPG

Nathalie Fagnan Named President and Chief Executive Officer of Héma-Québec


MONTRÉAL, Jan. 30, 2019 /CNW Telbec/ - Martine Carré, chair of the board of directors of Héma-Québec, is pleased to announce the appointment of Nathalie Fagnan, CPA, CA, as president and chief executive officer of Héma-Québec. Ms. Fagnan officially assumes her duties today.

Nathalie Fagnan Named President and Chief Executive Officer of Héma-Québec (CNW Group/Héma-Québec)

"The board of directors and I are very pleased to welcome Nathalie Fagnan. She will have no trouble quickly immersing herself in Héma-Québec's culture to carry on the transformation of the organization," said Ms. Carré. "Ms. Fagnan has a strategic mind and a solid background in operations management and finance. She has worked for major corporations in Canada and the United States and has many accomplishments in organizational transformation to her credit. Her experience will be a major asset in achieving the ambitions of our organization and meeting the many challenges that it faces today."

Ms. Fagnan holds a Bachelor's degree in business administration from HEC and is a member of the Ordre des comptables professionnels agréés. She has held several executive-level positions within internationally renowned service companies and currently serves on the boards of La Presse and the Théâtre Prospero/Groupe La Veillée. Until recently, she was executive vice-president and chief operating officer at Publicis North America, a world leader in communications and consultancy services for major transformation projects.

Previously, Ms. Fagnan was vice-president and chief operating officer at the firm Raymond Chabot Grant Thornton (RCGT), where she played a strategic role in the major transformation of the organization.

Prior to joining RCGT, she worked for more than 15 years at Publicis Canada where she held several financial management positions. In the nine years before leaving the firm, she served as executive vice-president, chief financial officer and member of the Canadian management committee.

About Héma-Québec

Héma-Québec's mission is to efficiently meet the needs of the Québec population for quality blood and other biological products of human origin.

Héma-Québec encompasses 1,300 employees and nearly 225,000 blood, stem cell, mother's milk and human tissue donors, in addition to thousands of blood drive volunteers. Each year, Héma-Québec delivers some 750,000 human biological products to Québec hospitals to meet the needs of patients.

Give Blood. Give Life.

Original text in French. In the event of a discrepancy between the English and French versions, the latter will prevail.

www.hema-quebec.qc.ca

 

SOURCE Héma-Québec


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: